245 results on '"Nordenskjöld, Bo"'
Search Results
2. Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
3. Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
4. PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
5. MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit
6. Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial
7. The effects of PTPN2 loss on cell signalling and clinical outcome in relation to breast cancer subtype
8. PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer
9. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
10. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
11. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
12. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
13. Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer
14. Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer
15. Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial
16. C–X–C ligand 10 and C–X–C receptor 3 status can predict tamoxifen treatment response in breast cancer patients
17. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer
18. Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
19. Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
20. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
21. IP6K2 predicts favorable clinical outcome of primary breast cancer
22. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer
23. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen
24. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial
25. In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients
26. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information
27. Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature.
28. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
29. Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
30. RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer
31. Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
32. Amplification of HSD17B1 and ERBB2 in primary breast cancer
33. A comparison between flow cytometric assessment of S-phase fraction and Nottingham histologic grade as prognostic instruments in breast cancer
34. Applying the Nottingham Prognostic Index to a Swedish breast cancer population
35. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial
36. DNA ploidy and S-phase in recurrent astrocytomas: a retrospective study by flow cytometry of deparaffinized specimens
37. Hypoxia inducible factor-1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response
38. S-phase determination of immunoselected cytokeratin-containing breast cancer cells improves the prediction of recurrence
39. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma
40. Coronary Heart Disease Mortality After 5 Years of Adjuvant Tamoxifen Therapy: Results from a Randomized Trial
41. Tumor-Specific Expression of Vascular Endothelial Growth Factor Receptor 2 but Not Vascular Endothelial Growth Factor or Human Epidermal Growth Factor Receptor 2 Is Associated With Impaired Response to Adjuvant Tamoxifen in Premenopausal Breast Cancer
42. Mutation and Accumulation of p53 Related to Results of Adjuvant Therapy of Postmenopausal Breast Cancer Patients
43. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
44. Long-term effects of mammography screening: updated overview of the Swedish randomised trials
45. Akt kinases in breast cancer and the results of adjuvant therapy
46. Interrelations of clinicopathologic variables and their prognostic value in colorectal adenocarcinoma
47. Decreased tumor cell proliferation as an indicator of the effect of preoperative radiotherapy of rectal cancer
48. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
49. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
50. Influence of S-phase fraction on metastatic pattern and post-recurrence survival in a randomized mammography screening trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.